1. Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method.
- Author
-
Saito A, Hiraga Y, Watanabe A, Saito A, Shimada K, Kobayashi H, Odagiri S, Miki F, Soejima R, Oizumi K, Hara K, and Nakashima M
- Subjects
- Adult, Aged, Aged, 80 and over, Bacteria metabolism, Bacterial Infections drug therapy, Body Temperature, Double-Blind Method, Female, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Models, Chemical, Placebos, Time Factors, Anti-Bacterial Agents therapeutic use, Cefmenoxime analogs & derivatives, Cefmenoxime therapeutic use, Cephalosporins therapeutic use, Respiratory Tract Infections drug therapy
- Abstract
In a double-blind study, the efficacy and safety of the novel cephem antibiotic cefcapene pivoxil (CFPN-PI; 450 mg/day) was compared with cefteram pivoxil (CFTM-PI; 600 mg/day) in 171 patients with chronic respiratory tract infections. There was no significant difference between the clinical efficacy of the two drugs (80.2% for CFPN-PI versus 78.9% for CFTM-PI). There was no significant difference in the rate of elimination of the causative bacteria (60.5% for CFPN-PI versus 65.9% for CFTM-PI). Side-effects were observed in 6.0% of patients treated with CFPN-PI compared with 6.4% of patients treated with CFTM-PI. There were no significant differences in incidence of abnormal laboratory findings following treatment with the two drugs (13.9% for each), and none of the side-effects was severe. We conclude that CFPN-PI (450 mg/day) was as effective and as well tolerated as CFTM-PI (600 mg/day) in the treatment of chronic respiratory tract infections.
- Published
- 2004
- Full Text
- View/download PDF